newsfilter
← Latest News
GlobeNewswire·

Kaplan Fox Encourages Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors to Contact the Firm Regarding an Investigation of Possible Securities Law Violations

  • Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).
  • On November 3, 2026, Madrigal filed its Form 10-Q revealing a whistleblower complaint filed by a former employee on October 9, 2026, alleging retaliation under the Sarbanes-Oxley Act.
  • The Complaint claims the plaintiff raised internal concerns about data and reporting practices before resigning in January 2026, seeking monetary damages, which Madrigal disputes.
  • Madrigal stock price declined 8.08% from $431.16 on November 2, 2026, to $396.32 on November 3, 2026, following the announcement.
  • Kaplan Fox & Kilsheimer LLP is a law firm with over 50 years of experience in securities litigation, having secured over $10 billion in recoveries for clients.
  • The firm is accepting contact from Madrigal investors who have suffered losses or possess information relevant to the investigation.
Company
Kaplan Fox & Kilsheimer, LLP
Keywords
Kaplan Fox & Kilsheimer, LLP, MDGL Investor Alert, MDGL Investigation, NASDAQ: MDGL, $MDGL, Shareholder Alert, Securities Investigation, Kaplan Fox, Class Action